STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY
RecruitingOBSERVATIONAL
Enrollment
10,000
Participants
Timeline
Start Date
February 1, 2022
Primary Completion Date
February 28, 2024
Study Completion Date
February 28, 2052
Conditions
Malignacy, Hemoglobinopathie
Trial Locations (1)
09121
RECRUITING
Azienda Ospedaliera Universitaria Di Cagliari, Cagliari
All Listed Sponsors
lead
Società Italiana Talassemie ed Emoglobinopatie
OTHER
NCT05286138 - STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY | Biotech Hunter | Biotech Hunter